+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Immune Checkpoint Inhibitors - Global Market Trajectory & Analytics

  • ID: 5309487
  • Report
  • April 2021
  • Region: Global
  • 146 pages
  • Global Industry Analysts, Inc
Global Immune Checkpoint Inhibitors Market to Reach $50.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Immune Checkpoint Inhibitors estimated at US$14.6 Billion in the year 2020, is projected to reach a revised size of US$50.7 Billion by 2027, growing at a CAGR of 19.4% over the analysis period 2020-2027. CLTA-4 Inhibitors, one of the segments analyzed in the report, is projected to record a 19.7% CAGR and reach US$10.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PD-1 segment is readjusted to a revised 18.5% CAGR for the next 7-year period.



The U.S. Market is Estimated at $4.4 Billion, While China is Forecast to Grow at 16.2% CAGR

The Immune Checkpoint Inhibitors market in the U.S. is estimated at US$4.4 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$7.4 Billion by the year 2027 trailing a CAGR of 16.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.6% and 17.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.

PD-L1 Inhibitors Segment to Record 22.5% CAGR

In the global PD-L1 Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 22.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.7 Billion in the year 2020 will reach a projected size of US$7.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.4 Billion by the year 2027.

Select Competitors (Total 42 Featured):
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fortress Biotech, Inc.
  • Immutep Ltd.
  • Merck & Co., Inc.
  • Merck KGaA
  • Novartis International AG
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for CLTA-4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for CLTA-4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for PD-1 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for PD-1 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 7: World Current & Future Analysis for PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 9: World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 11: World Current & Future Analysis for Bladder cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Bladder cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 13: World Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World 7-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 15: World Current & Future Analysis for Hodgkin lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 16: World 7-Year Perspective for Hodgkin lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 17: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 18: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
III. MARKET ANALYSIS
  • Table 19: USA Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: USA 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 21: USA Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 22: USA 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 23: Canada Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 24: Canada 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 25: Canada Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: Canada 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 27: Japan Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 28: Japan 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 29: Japan Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 30: Japan 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 31: China Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: China 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 33: China Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 34: China 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 35: Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 36: Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 37: Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 39: Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 40: Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 41: France Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 42: France 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 43: France Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: France 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 45: Germany Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 46: Germany 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 47: Germany Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 48: Germany 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 49: Italy Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: Italy 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 51: Italy Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 52: Italy 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 53: UK Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 54: UK 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 55: UK Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: UK 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 57: Rest of Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 58: Rest of Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 59: Rest of Europe Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 60: Rest of Europe 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 61: Asia-Pacific Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: Asia-Pacific 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 63: Asia-Pacific Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 64: Asia-Pacific 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
  • Table 65: Rest of World Current & Future Analysis for Immune Checkpoint Inhibitors by Drug Class - CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 66: Rest of World 7-Year Perspective for Immune Checkpoint Inhibitors by Drug Class - Percentage Breakdown of Value Sales for CLTA-4 Inhibitors, PD-1 and PD-L1 Inhibitors for the Years 2020 & 2027
  • Table 67: Rest of World Current & Future Analysis for Immune Checkpoint Inhibitors by Application - Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: Rest of World 7-Year Perspective for Immune Checkpoint Inhibitors by Application - Percentage Breakdown of Value Sales for Lung Cancer, Bladder cancer, Melanoma, Hodgkin lymphoma and Other Applications for the Years 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 42
Note: Product cover images may vary from those shown
Adroll
adroll